Payment overview · 2025
General Payments
$1,019.39
49 reported records · 23 companies
Healthcare provider profile · identity verified
Elina Levkoff, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PALM BEACH GARDENS, FL · NPI 1376973156
Verified facts
What the public records show
CMS Open Payments records show Elina Levkoff, M.D. received $1,019.39 in general payments during 2025 across 49 reported records.
PFIZER INC. accounted for 10.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $105.01 | 10.3% | 5 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $102.31 | 10.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.20 | 8.7% | 5 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $65.80 | 6.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.50 | 6.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.00 | 6.1% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $53.26 | 5.2% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.47 | 4.8% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $47.89 | 4.7% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $47.07 | 4.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $45.21 | 4.4% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $39.77 | 3.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.21 | 3.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.90 | 3.1% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $29.50 | 2.9% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $24.22 | 2.4% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $23.91 | 2.4% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.83 | 2.1% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $20.18 | 2.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.50 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.65 | 1.5% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.10 | 1.4% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$13.90 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,019.39 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $105.01 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $105.01 | 5 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $102.31 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $71.54 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $71.54 | 4 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $65.80 | 3 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $53.26 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $48.47 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $47.07 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $47.07 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $45.21 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.67 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $38.21 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $32.08 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.90 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.92 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $29.50 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 578 | 203 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 96 |
| Lisinopril | Lisinopril | 270 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 237 | 82 |
| Losartan Potassium | Losartan Potassium | 220 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 218 | 78 |
| Sertraline Hcl | Sertraline Hcl | 192 | 61 |
| Omeprazole | Omeprazole | 190 | 76 |
| Metformin Hcl | Metformin Hcl | 159 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 60 |
| Simvastatin | Simvastatin | 142 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 45 |
| Gabapentin | Gabapentin | 121 | 53 |
| Montelukast Sodium | Montelukast Sodium | 93 | 33 |
| Eliquis | Apixaban | 87 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 27 |
| Allopurinol | Allopurinol | 63 | 23 |
| Mounjaro | Tirzepatide | 61 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 25 |
| Alprazolam | Alprazolam | 60 | 32 |
| Bupropion Xl | Bupropion Hcl | 60 | 20 |
| Temazepam | Temazepam | 58 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 27 |
| Alendronate Sodium | Alendronate Sodium | 54 | 21 |
| Ezetimibe | Ezetimibe | 51 | 19 |
| Trazodone Hcl | Trazodone Hcl | 51 | 18 |
| Synthroid | Levothyroxine Sodium | 49 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 18 |
| Atenolol | Atenolol | 42 | 14 |
| Lorazepam | Lorazepam | 42 | 22 |
| Clonazepam | Clonazepam | 39 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 15 |
| Azithromycin | Azithromycin | 37 | 36 |
| Finasteride | Finasteride | 36 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 24 |
| Valsartan | Valsartan | 34 | 12 |
| Famotidine | Famotidine | 32 | 12 |
| Carvedilol | Carvedilol | 31 | 14 |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 18 |
| Cephalexin | Cephalexin | 27 | 25 |
| Estradiol | Estradiol | 27 | 16 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Furosemide | Furosemide | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Prednisone | Prednisone | 20 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | 11 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 11 |
| Baclofen | Baclofen | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 13 | 12 |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,019.39 · 49 records | PFIZER INC. | AJOVY, AUSTEDO XR, BRIUMVI, CAPVAXIVE, Cologuard Collection Kit, HYQVIA, KEVEYIS, NURTEC ODT, ONPATTRO, OTEZLA, Ocrevus Zunovo, Ozempic, PRECIVITYAD2, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TYSABRI, The Cologuard Plus Collection Kit, UBRELVY, ULTOMIRIS, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, Wegovy, Xeomin, ZAVZPRET, Zilbrysq | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error